Sunshine Biopharma (SBFM) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Sunshine Biopharma (SBFM) over the last 5 years, with Q1 2025 value amounting to -$0.44.
- Sunshine Biopharma's EPS (Weighted Average and Diluted) rose 7800.0% to -$0.44 in Q1 2025 from the same period last year, while for Mar 2025 it was -$2.34, marking a year-over-year increase of 6335.43%. This contributed to the annual value of -$7.32 for FY2024, which is 9791.77% up from last year.
- Sunshine Biopharma's EPS (Weighted Average and Diluted) amounted to -$0.44 in Q1 2025, which was up 7800.0% from -$3.08 recorded in Q4 2024.
- Sunshine Biopharma's 5-year EPS (Weighted Average and Diluted) high stood at $0.26 for Q4 2021, and its period low was -$97.47 during Q4 2023.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$9.37, with a median of -$0.34 in 2025.
- Per our database at Business Quant, Sunshine Biopharma's EPS (Weighted Average and Diluted) crashed by 619306.46% in 2023 and then skyrocketed by 9684.46% in 2024.
- Over the past 5 years, Sunshine Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.26 in 2021, then plummeted by 706.43% to -$1.55 in 2022, then crashed by 6193.06% to -$97.47 in 2023, then surged by 96.84% to -$3.08 in 2024, then soared by 85.69% to -$0.44 in 2025.
- Its last three reported values are -$0.44 in Q1 2025, -$3.08 for Q4 2024, and -$2.0 during Q1 2024.